Anthos was founded in 2019 by Novartis and the private equity firm Blackstone Life Sciences. Its most advanced drug candidate, abelacimab, is a monoclonal antibody designed to prevent strokes and ...
Novartis has agreed to buy Anthos from private equity firm Blackstone for $3.1 billion, taking Factor XI inhibitor abelacimab back in-house.
Novartis has agreed to buy Anthos from private equity firm Blackstone for $3.1 billion, taking Factor XI inhibitor abelacimab back in-house.
Update 12:12 ET. Adds response from Corsair Capital. Blackstone (NYSE:BX) and Corsair Capital are looking to sell First Eagle Investment Management for more than $4B, the Financial Times reported ...
Ares, CD&R and Neuberger Berman target retail apparel; Life science companies ripe for PE investment
In early January came news that Marquee Brands, which is backed by Neuberger Berman , acquired Laura Ashley, the iconic London-based brand that sells home furnishings and fashion items. The seller was ...
Effective Jan. 1, 2025, comanager Stephen Sullens stepped down from Blackstone Alternative Multi-Strategy and retired from the industry. On the same day, Stephen Zhu, managing director of ...
After hours: 7:59:07 pm GMT-5 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback